Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • zongertinib
Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Posted inClinical Updates Wellness & Lifestyle

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

Posted by By MedXY 08/01/2025
Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.
Read More
  • Functional MRI Brain Activation as a Predictor of Response to TNF Inhibition in Rheumatoid Arthritis: Insights from the PreCePra Phase 3 Study
  • Comparative Efficacy and Safety of Limertinib versus Gefitinib in First-Line Treatment of EGFR-Mutated Advanced NSCLC: A Phase 3 Randomized Trial
  • Sarilumab in Relapsing Polymyalgia Rheumatica: Clinical Efficacy and Patient-Reported Outcomes from Recent Phase 3 Trials
  • Once-Weekly Insulin Regimens in Type 2 Diabetes: Comparative Efficacy, Safety, and Clinical Implications from COMBINE 3 and QWINT Trials
  • Automated Insulin Delivery in Young Children with Type 1 Diabetes: Insights from the LENNY Trial
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics breast cancer clinical trial clinical trials diabetes diagnosis diet epidemiology exercise FDA FDA approval GLP-1 health healthcare Hypertension immunotherapy lifestyle lifestyle intervention longevity maternal health men's health Menopause mental health nutrition obesity older adults PCOS Physical Activity Pregnancy prevention public health randomized trial semaglutide sexual health sleep stroke treatment type 2 diabetes Vaccine walking weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top